Wire · opportunities
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
The U.S. FDA approved MIMRYLO (rusfertide), the first hepcidin mimetic peptide therapy for adults with polycythemia vera, addressing erythrocytosis by controlling hematocrit levels and reducing phlebotomy burden. This approval triggers significant milestone payments and royalties for Protagonist Therapeutics and Takeda, based on positive Phase 3 trial results.
This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 28 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
You can now enter the polycythemia vera market with a drug proven to reduce phlebotomy needs and fatigue, shifting treatment standards. Takeda's commercial lead offers a clear partner to scale rapidly or a competitor to outpace.
◆ Coverage
12 sources · first reported 28 Aug 2026 · latest 1 Sep 2026
◆ Related on Wire
◆ Topics